The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders

Leukemia

Volumn 31, Issue 8, 2017, Pages 1661-1670

  Maslah, N ^a,b   Cassinat, B ^a,b   Verger, E ^a,b   Kiladjian, J J ^a,b   Velazquez, L ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 2; LNK PROTEIN, HUMAN; PROTEIN;

EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETIC VARIATION; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LNK GENE; LYMPHATIC LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SH2B3 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; ANIMAL; CHEMISTRY; GENETICS; HEMATOLOGIC DISEASE; MUTATION; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; POLYCYTHEMIA;

ANIMALS; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA; PROTEINS;

EID: 85026654141     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.139     Document Type: Review

References (72)

1. Velazquez L. The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis. Arch Immunol Ther Exp (Warsz) 2012; 60: 415-429.
2. Huang X, Li Y, Tanaka K, Moore KG, Hayashi JI. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1995; 92: 11618-11622.
3. Takaki S, Watts JD, Forbush KA, Nguyen NT, Hayashi J, Alberola-Ila J et al. Characterization of Lnk. An adaptor protein expressed in lymphocytes. J Biol Chem 1997; 272: 14562-14570.
4. Li Y, He X, Schembri-King J, Jakes S, Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol 2000; 164: 5199-5206.
5. Fitau J, Boulday G, Coulon F, Quillard T, Charreau B. The adaptor molecule Lnk negatively regulates tumor necrosis factor-alpha-dependent VCAM-1 expression in endothelial cells through inhibition of the ERK1 and-2 pathways. J Biol Chem 2006; 281: 20148-20159.
6. Kwon S-M, Suzuki T, Kawamoto A, Ii M, Eguchi M, Akimaru H et al. Pivotal role of lnk adaptor protein in endothelial progenitor cell biology for vascular regeneration. Circ Res 2009; 104: 969-977.
7. Wang T-C, Chiu H, Chang Y-J, Hsu T-Y, Chiu I-M, Chen L. The adaptor protein SH2B3 (Lnk) negatively regulates neurite outgrowth of PC12 cells and cortical neurons. PLoS ONE 2011; 6: e26433.
8. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnkdeficient mice. J Exp Med 2002; 195: 1599-1611.
9. Dhe-Paganon S, Werner ED, Nishi M, Hansen L, Chi Y-I, Shoelson SE. A phenylalanine zipper mediates APS dimerization. Nat Struct Mol Biol 2004; 11: 968-974.
10. Nishi M, Werner ED, Oh B-C, Frantz JD, Dhe-Paganon S, Hansen L et al. Kinase activation through dimerization by human SH2-B. Mol Cell Biol 2005; 25: 2607-2621.
11. Takizawa H, Kubo-Akashi C, Nobuhisa I, Kwon S-M, Iseki M, Taga T et al. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk. Blood 2006; 107: 2968-2975.
12. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007; 110: 3360-3364.
13. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005; 105: 4604-4612.
14. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008; 118: 2832-2844.
15. Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ, Varin-Blank N et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 2008; 112: 4039-4047.
16. Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010; 116: 5961-5971.
17. Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, Yamasaki A et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci USA 2007; 104: 2349-2354.
18. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002; 195: 151-160.
19. Takaki S, Sauer K, Iritani BM, Chien S, Ebihara Y, Tsuji K et al. Control of B cell production by the adaptor protein lnk. Definition Of a conserved family of signalmodulating proteins. Immunity 2000; 13: 599-609.
20. Ema H, Sudo K, Seita J, Matsubara A, Morita Y, Osawa M et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnkdeficient mice. Dev Cell 2005; 8: 907-914.
21. Buza-Vidas N, Antonchuk J, Qian H, Månsson R, Luc S, Zandi S et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 2006; 20: 2018-2023.
22. Cheng Y, Chikwava K, Wu C, Zhang H, Bhagat A, Pei D et al. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest 2016; 126: 1267-1281.
23. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004; 200: 569-580.
24. Takizawa H, Eto K, Yoshikawa A, Nakauchi H, Takatsu K, Takaki S. Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor protein through crosstalk between cytokine-and integrin-mediated signals. Exp Hematol 2008; 36: 897-906.
25. Takizawa H, Nishimura S, Takayama N, Oda A, Nishikii H, Morita Y et al. Lnk regulates integrin alphaIIbbeta3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010; 120: 179-190.
26. Wakioka T, Sasaki A, Mitsui K, Yokouchi M, Inoue A, Komiya S et al. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 1999; 13: 760-767.
27. Javadi M, Hofstätter E, Stickle N, Beattie BK, Jaster R, Carter-Su C et al. The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor. J Biol Chem 2012; 287: 26223-26234.
28. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009; 85: 957-965.
29. Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C. Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol Cell Biol 2006; 26: 6381-6394.
30. Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol 2013; 161: 811-820.
31. Jiang J, Balcerek J, Rozenova K, Cheng Y, Bersenev A, Wu C et al. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells. J Clin Invest 2012; 122: 2079-2091.
32. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120: 2058-2069.
33. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. Longterm survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124: 2507-2513, quiz 2615.
34. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
35. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
36. McMullin MF, Cario H. LNK mutations and myeloproliferative disorders. Am J Hematol 2016; 91: 248-251.
37. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
38. Oh ST, Zahn JM, Jones CD, Zhang B, Loh ML, Kantarjian H et al. Identification of novel LNK mutations in patients with chronic myeloproliferative neoplasms and related disorders. Blood 2010; 116: 315-315.
39. Ha J-S, Jeon D-S. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol 2011; 86: 866-868.
40. Hurtado C, Erquiaga I, Aranaz P, Miguéliz I, García-Delgado M, Novo FJ et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation. Leuk Res 2011; 35: 1537-1539.
41. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
42. Lasho TL, Tefferi A, Finke C, Pardanani A. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 2011; 25: 1056-1058.
43. Chen Y, Fang F, Hu Y, Liu Q, Bu D, Tan M et al. The polymorphisms in LNK gene correlated to the clinical type of myeloproliferative neoplasms. PLoS ONE 2016; 11: e0154183.
44. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363: 1189-1190.
45. Spolverini A, Pieri L, Guglielmelli P, Pancrazzi A, Fanelli T, Paoli C et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica 2013; 98: e101-e102.
46. McMullin MF, Wu C, Percy MJ, Tong W. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis. Am J Hematol 2011; 86: 962-964.
47. Camps C, Petousi N, Bento C, Cario H, Copley RR, McMullin MF et al. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica 2016; 101: 1306-1318.
48. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JHM et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767-2777.
49. Auburger G, Gispert S, Lahut S, Omür O, Damrath E, Heck M et al. 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World J Diabetes 2014; 5: 316-327.
50. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41: 342-347.
51. Hunt KA, Zhernakova A, Turner G, Heap GAR, Franke L, Bruinenberg M et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40: 395-402.
52. Zhernakova A, Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. Am J Hum Genet 2010; 86: 970-977.
53. Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O et al. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun 2010; 11: 439-445.
54. Lavrikova EY, Nikitin AG, Kuraeva TL, Peterkova VA, Tsitlidze NM, Chistiakov DA et al. The carriage of the type 1 diabetes-associated R262W variant of human LNK correlates with increased proliferation of peripheral blood monocytes in diabetic patients. Pediatr Diabetes 2011; 12: 127-132.
55. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L et al. Genomewide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41: 666-676.
56. Ikram MK, Sim X, Xueling S, Jensen RA, Cotch MF, Hewitt AW et al. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. PLoS Genet 2010; 6: e1001184.
57. Flister MJ, Hoffman MJ, Lemke A, Prisco SZ, Rudemiller N, O'Meara CC et al. SH2B3 is a genetic determinant of cardiac inflammation and fibrosis. Circ Cardiovasc Genet 2015; 8: 294-304.
58. Dale BL, Madhur MS. Linking inflammation and hypertension via LNK/SH2B3. Curr Opin Nephrol Hypertens 2016; 25: 87-93.
59. Daly ME. Determinants of platelet count in humans. Haematologica 2011; 96: 10-13.
60. Soranzo N, Spector TD, Mangino M, Kühnel B, Rendon A, Teumer A et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41: 1182-1190.
61. Ganesh SK, Zakai NA, van Rooij FJA, Soranzo N, Smith AV, Nalls MA et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 2009; 41: 1191-1198.
62. Lesteven E, Picque M, Conejero Tonetti C, Giraudier S, Varin-Blank N, Velazquez L et al. Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood 2014; 123: 794-796.
63. Wang W, Tang Y, Wang Y, Tascau L, Balcerek J, Tong W et al. LNK/SH2B3 loss of function promotes atherosclerosis and thrombosis. Circ Res 2016; 19: e91-e103.
64. Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 2016; 128: 1121-1128.
65. Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B et al. Genomewide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 2015; 6: 7138.
66. Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. J Natl Cancer Inst 2015; 107: djv246.
67. Rumi E, Harutyunyan AS, Pietra D, Feenstra JDM, Cavalloni C, Roncoroni E et al. LNK mutations in familial myeloproliferative neoplasms. Blood 2016; 128: 144-145.
68. Loscocco GG, Mannarelli C, Pacilli A, Fanelli T, Rotunno G, Gesullo F et al. Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. Am J Hematol 2016; 91: E356.
69. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
70. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166.
71. Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood 2013; 122: 2425-2432.
72. Lindqvist CM, Lundmark A, Nordlund J, Freyhult E, Ekman D, Carlsson Almlöf J et al. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapseassociated genes. Oncotarget 2016; 7: 64071-64088.